Clinical Trials Browser

NCT05422794 2026-03-18

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Phase 1 Recruiting

57 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06767527 2026-03-16

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

416 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06841354 2026-03-13

TroFuse-011

Phase 3 Recruiting

1,000 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06926868 2026-03-11

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

500 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06802757 2026-02-25

PRISM-TNBC

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

37 enrolled 8 charts

Breast

Triple Negative Breast Neoplasms

NCT04251533 2026-02-13

EPIK-B3

Phase 3 Active not recruiting

137 enrolled 21 charts

Breast

Triple Negative Breast Neoplasms

NCT06279364 2026-01-27

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3 Recruiting

524 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

Phase 3 Completed

184 enrolled 15 charts

Breast

Triple Negative Breast Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2 Not yet recruiting

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07178171 2025-11-24

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Phase 1 Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Breast

Triple Negative Breast Neoplasms

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase 2 Terminated

6 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Phase 2 Recruiting

520 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04159142 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Phase 2 Recruiting

414 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Phase 2 Not yet recruiting

150 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05382299 2025-09-05

ASCENT-03

Phase 3 Active not recruiting

623 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05582538 2025-08-24

ATRiBRAVE

Phase 2 Recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03893955 2025-08-12

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

150 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Triple Negative Breast Neoplasms

NCT04085276 2025-06-11

TORCHLIGHT

Phase 3 Active not recruiting

531 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

Phase 2 Active not recruiting

29 enrolled 11 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06975644 2025-05-22

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

Phase NA Not yet recruiting

55 enrolled

Breast

Triple Negative Breast Neoplasms